By Chris Wack
Pfizer Inc. (PFE) said Wednesday that it saw positive top-line results from a Phase 3 pivotal study for its investigational oral Janus kinase 1 inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.
The pharmaceutical company said in a release that top-line results showed that by week 12, the percentage of patients achieving each co-primary efficacy endpoint and each key secondary endpoint with either dose of abrocitinib was statistically significantly higher than placebo.
Pfizer said the results demonstrate response to treatment for a statistically significant number of patients during the first two to four weeks following the first dose.
The company said that safety results showed that both doses of abrocitinib were well-tolerated and there were no unexpected safety events. The discontinuation rates due to an adverse event were low in each treatment arm compared to placebo.
Write to Chris Wack at email@example.com